Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient

The Lancet

Volumn 341, Issue 8853, 1993, Pages 1151-

  Mcleod, H L ^a,b   Miller, D R ^a,b   Evans, W E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; CASE REPORT; CHILD; FEMALE; HEART TRANSPLANTATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL RATE;

AZATHIOPRINE; BONE MARROW; CASE REPORT; CHILD, PRESCHOOL; DEPRESSION, CHEMICAL; ERYTHROCYTES; FEMALE; HEART TRANSPLANTATION; HUMAN; MALE; METHYLTRANSFERASES;

EID: 0027285234     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)93168-Z     Document Type: Letter

References (5)

1. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
2. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia
3. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity
4. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
5. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia